A prospective, multicenter, single arm, open-label, phase III study to assess the safety and efficacy of bosentan in patients with digital ulcers associated with systemic sclerosis (SSc)
Latest Information Update: 31 May 2016
At a glance
- Drugs Bosentan (Primary)
- Indications Systemic scleroderma; Ulcer
- Focus Adverse reactions; Registrational
- Sponsors Actelion Pharmaceuticals
- 31 May 2016 New trial record